LIMBITROL

Clinical safety rating: caution

Comprehensive clinical and safety monograph for LIMBITROL (LIMBITROL).

How it works

Limbitrol is a combination of chlordiazepoxide (a benzodiazepine) and amitriptyline (a tricyclic antidepressant). Chlordiazepoxide enhances GABA-A receptor activity, producing anxiolytic and sedative effects. Amitriptyline inhibits serotonin and norepinephrine reuptake, elevating mood and reducing pain. The combination is used for depression with anxiety.

What the body does with it

Metabolism	Chlordiazepoxide: Hepatic via CYP3A4, active metabolite (nordiazepam), long half-life. Amitriptyline: Hepatic via CYP2D6, CYP3A4, CYP2C19; active metabolite (nortriptyline).
Excretion	Renal (approximately 70-80% as metabolites, 1-3% unchanged) and fecal (20-30% via biliary elimination for chlordiazepoxide component; amitriptyline is primarily excreted renally as metabolites, 10-15% unchanged).
Half-life	Amitriptyline: 20-30 hours (range 10-46 h) with a terminal elimination half-life of ~24 h; clinical significance requires 7-14 days to reach steady state. Chlordiazepoxide: 5-30 hours (up to 48 h for active metabolite desmethylchlordiazepoxide).
Protein binding	Amitriptyline: 85-95% bound (primarily to α1-acid glycoprotein and albumin); chlordiazepoxide: 96-98% bound (predominantly to albumin).
Volume of Distribution	Amitriptyline: 15-18 L/kg (Vd ~1–2 L/kg for amitriptyline, but high tissue binding leads to large apparent Vd); chlordiazepoxide: 0.3-0.5 L/kg. Clinical meaning: extensive tissue distribution, large reservoir in peripheral compartments.
Bioavailability	Oral: 40-60% for amitriptyline (first-pass metabolism reduces bioavailability; range 30-70%); chlordiazepoxide: 100% (well absorbed with minimal first-pass effect).
Onset of Action	Oral: 30-60 minutes for initial sedative and anxiolytic effects; antidepressant effects require 2-4 weeks of continuous dosing.
Duration of Action	Sedative/anxiolytic effects last 4-8 hours after a single oral dose; antidepressant effects persist with chronic dosing; half-life supports once-daily dosing for maintenance.

Classification & Brands

Dosing & administration

1-2 tablets (5 mg chlordiazepoxide / 12.5 mg amitriptyline per tablet) orally 3-4 times daily. Maximum 6 tablets per day in divided doses.

Dosage form	TABLET
Renal impairment	eGFR <10 mL/min: Avoid use. eGFR 10-30 mL/min: Reduce dose by 50% and monitor for toxicity. eGFR >30 mL/min: No adjustment needed.
Liver impairment	Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50%. Child-Pugh Class C: Avoid use.
Pediatric use	Not recommended for use in children under 12 years. Weight-based dosing not established; consider adult-like dosing with caution in adolescents over 12 years.
Geriatric use	Initial dose: 1 tablet (5 mg chlordiazepoxide / 12.5 mg amitriptyline) orally once daily, increase slowly. Maximum 4 tablets per day. Avoid in elderly due to increased risk of sedation, falls, and cognitive impairment.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for LIMBITROL (LIMBITROL).

Breastfeeding	Excreted in breast milk; M/P ratio not well-defined. Use caution; monitor infant for sedation, poor feeding, and respiratory depression. Alternative agents preferred.
Teratogenic Risk	First trimester: Increased risk of congenital malformations, including neural tube defects and cardiovascular anomalies. Avoid use. Second trimester: Possible fetal growth restriction and preterm birth. Third trimester: Risk of neonatal withdrawal syndrome and respiratory depression at delivery.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS - Antidepressants increased the risk of suicidal thinking and behavior in short-term studies in children, adolescents, and young adults. Monitor closely for clinical worsening, suicidality, or unusual changes in behavior.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Concomitant use with MAOIs or within 14 days of MAOI discontinuation","Recent myocardial infarction","Uncontrolled angle-closure glaucoma","Urinary retention","Hypersensitivity to chlordiazepoxide, amitriptyline, or any component","Concurrent use with other benzodiazepines or TCAs (additive effects)","Pregnancy (especially first trimester) and lactation"]

Clinical Precautions

Precautions

["Risk of suicidal thoughts and behaviors","Activation of mania/hypomania","Seizure threshold lowering","Cardiotoxicity (QT prolongation, arrhythmias) especially in overdose","Sedation and cognitive impairment, caution with driving","Potential for abuse and dependence (benzodiazepine component)","Anticholinergic effects (dry mouth, constipation, blurred vision)","Hepatic impairment may require dose adjustment"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

LIMBITROL

Clinical safety rating: caution

Comprehensive clinical and safety monograph for LIMBITROL (LIMBITROL).

How it works

What the body does with it

Metabolism	Chlordiazepoxide: Hepatic via CYP3A4, active metabolite (nordiazepam), long half-life. Amitriptyline: Hepatic via CYP2D6, CYP3A4, CYP2C19; active metabolite (nortriptyline).
Excretion	Renal (approximately 70-80% as metabolites, 1-3% unchanged) and fecal (20-30% via biliary elimination for chlordiazepoxide component; amitriptyline is primarily excreted renally as metabolites, 10-15% unchanged).
Half-life	Amitriptyline: 20-30 hours (range 10-46 h) with a terminal elimination half-life of ~24 h; clinical significance requires 7-14 days to reach steady state. Chlordiazepoxide: 5-30 hours (up to 48 h for active metabolite desmethylchlordiazepoxide).
Protein binding	Amitriptyline: 85-95% bound (primarily to α1-acid glycoprotein and albumin); chlordiazepoxide: 96-98% bound (predominantly to albumin).
Volume of Distribution	Amitriptyline: 15-18 L/kg (Vd ~1–2 L/kg for amitriptyline, but high tissue binding leads to large apparent Vd); chlordiazepoxide: 0.3-0.5 L/kg. Clinical meaning: extensive tissue distribution, large reservoir in peripheral compartments.
Bioavailability	Oral: 40-60% for amitriptyline (first-pass metabolism reduces bioavailability; range 30-70%); chlordiazepoxide: 100% (well absorbed with minimal first-pass effect).
Onset of Action	Oral: 30-60 minutes for initial sedative and anxiolytic effects; antidepressant effects require 2-4 weeks of continuous dosing.
Duration of Action	Sedative/anxiolytic effects last 4-8 hours after a single oral dose; antidepressant effects persist with chronic dosing; half-life supports once-daily dosing for maintenance.

Classification & Brands

Dosing & administration

1-2 tablets (5 mg chlordiazepoxide / 12.5 mg amitriptyline per tablet) orally 3-4 times daily. Maximum 6 tablets per day in divided doses.

Dosage form	TABLET
Renal impairment	eGFR <10 mL/min: Avoid use. eGFR 10-30 mL/min: Reduce dose by 50% and monitor for toxicity. eGFR >30 mL/min: No adjustment needed.
Liver impairment	Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50%. Child-Pugh Class C: Avoid use.
Pediatric use	Not recommended for use in children under 12 years. Weight-based dosing not established; consider adult-like dosing with caution in adolescents over 12 years.
Geriatric use	Initial dose: 1 tablet (5 mg chlordiazepoxide / 12.5 mg amitriptyline) orally once daily, increase slowly. Maximum 4 tablets per day. Avoid in elderly due to increased risk of sedation, falls, and cognitive impairment.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for LIMBITROL (LIMBITROL).

Breastfeeding	Excreted in breast milk; M/P ratio not well-defined. Use caution; monitor infant for sedation, poor feeding, and respiratory depression. Alternative agents preferred.
Teratogenic Risk	First trimester: Increased risk of congenital malformations, including neural tube defects and cardiovascular anomalies. Avoid use. Second trimester: Possible fetal growth restriction and preterm birth. Third trimester: Risk of neonatal withdrawal syndrome and respiratory depression at delivery.
Fetal Monitoring